Post transcriptional regulation of plasminogen activator inhibitor type 2 gene expression [ 2004 - 2006 ]

Research Grant

Researchers: Prof Robert Medcalf (Principal investigator) ,  Dr Hong Yu

Brief description The process of wound healing, cell migration and the spread of cancers requires the recruitment of specialised proteases to the cell surface . These proteases act to degrade other proteins, mainly in the extracellular space, which in turn allows cells to move around, wounds to close, and blood clots to disappear. The plasminogen activating system is one of the enzyme systems involved in these events. One of the proteases that cleaves plasminogen to its active form, plasmin, is urokinase (u-PA) and the activity of u-PA is regulated by its natural inhibitor called plasminogen activator inhibitor type 2 (PAI-2). u-PA is strongly implicated in the progression of metastatic cancer and high levels of PAI-2 relative to u-PA is regularly seen as a positive prognostic indicator for metastatic cancer. In this situation, PAI-2 acts to limit the activity of u-PA thereby restricting the migration potential of the cancer. PAI-2 is unusual because it exists both inside and outside the cell. Outside the cell, PAI-2 acts to inhibit u-PA activity, while inside the cell, PAI-2 also plays a role in the inhibition of cell growth and differentiation. It is therefore important to understand how the production of PAI-2 is regulated in cells. A significant component of PAI-2 regulation occurs post-transcriptionally, particularly at the level of mRNA stability. We have identified some of the proteins that bind to PAI-2 mRNA and influence its longevity in the cell. This project aims to further undertand how these as well as other PAI-2 mRNA binding proteins influence the expression of the PAI-2 gene.

Funding Amount $AUD 318,000.00

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant